中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2011年
34期
34-36
,共3页
苏稼航%马卫霞%伊洪莉%姜淑娟
囌稼航%馬衛霞%伊洪莉%薑淑娟
소가항%마위하%이홍리%강숙연
血糖%骨密度%氟替卡松
血糖%骨密度%氟替卡鬆
혈당%골밀도%불체잡송
Blood glucose%Bone density%Fluticasone propionate
目的 观察沙美特罗丙酸氟替卡松吸入对老年慢性阻塞性肺疾病(COPD)合并2型糖尿病(T2DM)患者糖代谢及骨密度有无不良影响.方法 将31例老年COPD合并T2DM患者按随机数字表法分为两组,对照组14例,给予常规治疗,试验组17例,另外加用沙美特罗替卡松50/500μg每日2次,每次1吸,连续用药3个月,观察两组患者空腹血糖、餐后2h血糖、糖化血红蛋白、血浆皮质醇及骨密度水平的改变.结果 试验组患者的空腹血糖、餐后2h血糖、糖化血红蛋白、骨密度水平分别由治疗前的(5.25±0.21) mmol/L、(7.14±0.33) mmol/L、(5.58±0.26)％、(1.96±0.11)g/cm2变为治疗后的(5.31±0.27) mmol/L、( 7.22±0.29) mmol/L、(5.67±0.23)％、(2.03±0.15)g/cm2,差异无统计学意义(P＞0.05)；对照组患者的相应指标分别由治疗前的(5.33±0.35) mmol/L、(7.26±0.29) mmol/L、(5.62±0.19)％、(1.88±0.20) g/cm2变为治疗后的(5.36±0.31) mmol/L、(7.30±0.35)mmol/L、(5.69±0.26)％、(1.98±0.17) g/cm2,差异无统计学意义(P＞0.05)；两组患者组间比较差异亦无统计学意义(P＞0.05).两组患者治疗前后血浆皮质醇水平比较差异无统计学意义(P＞0.05).结论 沙美特罗替卡松吸入对老年COPD合并T2DM患者的糖代谢和骨密度无不良影响.
目的 觀察沙美特囉丙痠氟替卡鬆吸入對老年慢性阻塞性肺疾病(COPD)閤併2型糖尿病(T2DM)患者糖代謝及骨密度有無不良影響.方法 將31例老年COPD閤併T2DM患者按隨機數字錶法分為兩組,對照組14例,給予常規治療,試驗組17例,另外加用沙美特囉替卡鬆50/500μg每日2次,每次1吸,連續用藥3箇月,觀察兩組患者空腹血糖、餐後2h血糖、糖化血紅蛋白、血漿皮質醇及骨密度水平的改變.結果 試驗組患者的空腹血糖、餐後2h血糖、糖化血紅蛋白、骨密度水平分彆由治療前的(5.25±0.21) mmol/L、(7.14±0.33) mmol/L、(5.58±0.26)％、(1.96±0.11)g/cm2變為治療後的(5.31±0.27) mmol/L、( 7.22±0.29) mmol/L、(5.67±0.23)％、(2.03±0.15)g/cm2,差異無統計學意義(P＞0.05)；對照組患者的相應指標分彆由治療前的(5.33±0.35) mmol/L、(7.26±0.29) mmol/L、(5.62±0.19)％、(1.88±0.20) g/cm2變為治療後的(5.36±0.31) mmol/L、(7.30±0.35)mmol/L、(5.69±0.26)％、(1.98±0.17) g/cm2,差異無統計學意義(P＞0.05)；兩組患者組間比較差異亦無統計學意義(P＞0.05).兩組患者治療前後血漿皮質醇水平比較差異無統計學意義(P＞0.05).結論 沙美特囉替卡鬆吸入對老年COPD閤併T2DM患者的糖代謝和骨密度無不良影響.
목적 관찰사미특라병산불체잡송흡입대노년만성조새성폐질병(COPD)합병2형당뇨병(T2DM)환자당대사급골밀도유무불량영향.방법 장31례노년COPD합병T2DM환자안수궤수자표법분위량조,대조조14례,급여상규치료,시험조17례,령외가용사미특라체잡송50/500μg매일2차,매차1흡,련속용약3개월,관찰량조환자공복혈당、찬후2h혈당、당화혈홍단백、혈장피질순급골밀도수평적개변.결과 시험조환자적공복혈당、찬후2h혈당、당화혈홍단백、골밀도수평분별유치료전적(5.25±0.21) mmol/L、(7.14±0.33) mmol/L、(5.58±0.26)％、(1.96±0.11)g/cm2변위치료후적(5.31±0.27) mmol/L、( 7.22±0.29) mmol/L、(5.67±0.23)％、(2.03±0.15)g/cm2,차이무통계학의의(P＞0.05)；대조조환자적상응지표분별유치료전적(5.33±0.35) mmol/L、(7.26±0.29) mmol/L、(5.62±0.19)％、(1.88±0.20) g/cm2변위치료후적(5.36±0.31) mmol/L、(7.30±0.35)mmol/L、(5.69±0.26)％、(1.98±0.17) g/cm2,차이무통계학의의(P＞0.05)；량조환자조간비교차이역무통계학의의(P＞0.05).량조환자치료전후혈장피질순수평비교차이무통계학의의(P＞0.05).결론 사미특라체잡송흡입대노년COPD합병T2DM환자적당대사화골밀도무불량영향.
Objective To observe the effects of salmeterol fluticasone on the glucose metabolism and bone density of the elderly patients with chronic obstructive pulmonary disease (COPD) combined with type 2 diabetes mellitus (T2DM).Methods Thirty-one patients with COPD combined with T2DM were divided into 2 groups by random digits table,14 cases in control group were given conventional therapy,17 cases in experimental group were given conventional therapy and fluticasone propionate 50/500 μg,twice a day,for 3 months.The fasting blood glucose,postprandial 2 hours glucose,glycosylated hemoglobin,plasma cortisol and bone density respectively before and after treatment were detected.Results In experimental group,the fasting blood glucose,postprandial 2 hours glucose,glycosylated hemoglobin and bone density before treatment was (5.25 ± 0.21 ) mmol/L,(7.14 ± 0.33 ) mmol/L,(5.58 ± 0.26 )％,( 1.96 ± 0.11 ) g/cm2,and after treatment was(5.31 ± 0.27 ) mmol/L,(7.22 ± 0.29 ) mmol/L,(5.67 ± 0.23 )％,(2.03 ± 0.15 ) g/cm2,there was no significant difference (P ＞ 0.05).In control groups,the fasting blood glucose,postprandial 2 hours glucose,glycosylated hemoglobin and bone density before treatment was (5.33 ± 0.35) mmol/L,( 7.26 ± 0.29 ) mmol/L,( 5.62 ± 0.19 )％,( 1.88 ± 0.20 ) g/cm2,and after treatment was ( 5.36 ± 0.31 ) mmol/L,(7.30 ± 0.35 ) mmol/L,( 5.69 ± 0.26 )％,( 1.98 ± 0.17 ) g/cm2,there was no significant difference (P ＞ 0.05 ).There was no significant difference in plasma cortisol before and after treatment in two groups (P ＞0.05).Conclusion Inhaling salmeterol fluticasone for elderly patients with COPD combined with T2DM is safe.
